U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06812780) titled 'A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389' on Feb. 03.
Brief Summary: The purpose of this study is to examine the safety and tolerability of AZD2389 in participants with hepatic impairment and participants with normal hepatic function.
Study Start Date: March 26
Study Type: INTERVENTIONAL
Condition:
Hepatic Impairment
Intervention:
DRUG: AZD2389
Single oral dose of AZD2389 in participants from all cohorts
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AstraZeneca
Published by HT Digital Content Services with permission from Health Daily Dige...